Phaseline

Companies › Guerbet

Guerbet: clinical trials, targets and expected readouts

5 active drug programs in 6 registered trials: 5 Phase 4, 1 Phase 3; Oncology, Cardiovascular, Other; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Gadobenate dimeglumine
Gadolinium-based contrast agent for MRI
–Phase 4Motor FunctionDec 2028
Gadodiamide
Gadolinium-based contrast agent for MRI
–Phase 4Motor FunctionDec 2028
Gadoterate meglumine
Gadolinium-based contrast agent for MRI
–Phase 4Motor FunctionDec 2028
Gadoxetate disodium
Gadolinium-based contrast agent for MRI
–Phase 4Motor FunctionDec 2028
gadopiclenol
Gadolinium-based MRI contrast agent
–Phase 3Steno-occlusive Disease; Contrast Enhanced Images vs. Non-contrast ImagesDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06846853gadopiclenolPhase 4Contrast Enhanced Images vs. Non-contrast ImagesOtherJun 2026
NCT07348640gadopiclenolPhase 3Steno-occlusive DiseaseCardiovascularDec 2027
NCT04373564Gadoxetate disodiumPhase 4Motor FunctionOncologyDec 2028
NCT04373564Gadobenate dimegluminePhase 4Motor FunctionOncologyDec 2028
NCT04373564GadodiamidePhase 4Motor FunctionOncologyDec 2028
NCT04373564Gadoterate megluminePhase 4Motor FunctionOncologyDec 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Curium US FutureChem Verity Pharmaceuticals SecuraBio Fidia Farmaceutici

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.